ArticleAntimicrobial agents and chemotherapy2011
Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 100 citations in OpenAlex.
- Disseminated melioidosis due to ceftazidime-resistant Burkholderia pseudomallei in a Spanish traveler.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Genomic diversity and clade clustering ofiScience · 2026Article
- Case Report: Eschar-like subcutaneous lesion in disseminated melioidosis revealing anti-interferon-γ autoantibody-associated adult-onset immunodeficiency and a review of the literature.Frontiers in medicine · 2026Article
- Mortality among hospitalized children with melioidosis in Thailand: a retrospective national database analysis (2015-2023).The Lancet regional health. Southeast Asia · 2025Article
- Complete genome sequence of ceftazidime-resistantMicrobiology resource announcements · 2025Article
- Genomic insights into ceftazidime resistance inAntimicrobial agents and chemotherapy · 2025Article
- Rapid detection of antibiotic resistance in Burkholderia pseudomallei using MALDI-TOF mass spectrometry.Scientific reports · 2025Article
- Global Prevalence of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Development of Carbapenem Resistance While on Antibiotic Therapy in a Patient with Melioidosis.The American journal of tropical medicine and hygiene · 2025Article
- Article
- Virulome and phylogenomic profiling of a novel Burkholderia pseudomallei strain from an Indian clinical isolate.Molecular genetics and genomics : MGG · 2024Article
- The Rapid Emergence of HypervirulentTropical medicine and infectious disease · 2024Review
- Identification ofMicrobiology spectrum · 2024Article
- Shared challenges to the control of complex intracellular neglected pathogens.Frontiers in public health · 2024Review
- The Arabinose 5-Phosphate Isomerase KdsD Is Required for Virulence in Burkholderia pseudomallei.Journal of bacteriology · 2023Article
- Antibiotic susceptibility of clinicalAntimicrobial agents and chemotherapy · 2023Article
- DNase I and chitosan enhance efficacy of ceftazidime to eradicate Burkholderia pseudomallei biofilm cells.Scientific reports · 2023Article
- Effective Therapeutic Options for Melioidosis: Antibiotics versus Phage Therapy.Pathogens (Basel, Switzerland) · 2022Review
- Enhanced melioidosis surveillance in patients attending four tertiary hospitals in Yangon, Myanmar.Epidemiology and infection · 2021Article
- Genomic and RT-qPCR analysis of trimethoprim-sulfamethoxazole and meropenem resistance in Burkholderia pseudomallei clinical isolates.PLoS neglected tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
A 21-year survey conducted in northeast Thailand of antimicrobial resistance to parenteral antimicrobial drugs used to treat melioidosis identified 24/4,021 (0.6%) patients with one or more isolates resistant to ceftazidime (n = 8), amoxicillin-clavulanic acid (n = 4), or both drugs (n = 12). Two cases were identified at admission, and the remainder were detected a median of 15 days after starting antimicrobial therapy. Resistance to carbapenem drugs was not detected. These findings support the current prescribing recommendations for melioidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.